The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tejani, Mohamedtaki A, Cohen, Roger B, Mehra, Ranee
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921255/
https://www.ncbi.nlm.nih.gov/pubmed/20714355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921255/
https://www.ncbi.nlm.nih.gov/pubmed/20714355

Ejemplares similares